Sign In
Buy RNA
$12.17
-0.0800 (-0.653%)
At Close: Jun 03, 2026
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 21'st Feb 2024
SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
09:56am, Monday, 29'th Jan 2024
Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Jan 2024
SAN DIEGO , Jan. 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
08:30am, Friday, 05'th Jan 2024
Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 10
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st Dec 2023
SAN DIEGO , Dec. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
10:32am, Wednesday, 29'th Nov 2023
Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
10:09am, Tuesday, 28'th Nov 2023
Avidity Biosciences (NASDAQ: RNA ) stock is soaring in early trading after the company disclosed that it had expanded its partnership with a huge drugmaker, Bristol Myers Squibb (NYSE: BMY ). More Abo
Avidity Stock Soars on Collaboration Deal With Bristol Myers
07:43am, Tuesday, 28'th Nov 2023
Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.
Avidity Biosciences leaps on Bristol-Myers research tie-up
07:38am, Tuesday, 28'th Nov 2023
Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY). The pact is focused on the discovery, dev
Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Wednesday, 30'th Aug 2023
SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
07:52pm, Tuesday, 09'th May 2023
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.71 per share a year ago.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
01:04pm, Friday, 31'st Mar 2023
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key Study
09:20am, Thursday, 30'th Mar 2023
A key study from Avidity Biosciences remains on hold after a patient experienced a rare side effect, leading RNA stock to plummet Thursday. The post Avidity Bio Crashes 26% After 'Rarer Than Rare' Eve
Avidity's stock falls after sharing additional data about partial clinical hold
07:52am, Thursday, 30'th Mar 2023
Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic dy
